Get the Stockscreener App
2.72
5.88%
-0.17
After Hours:
2.74
0.02
+0.74%
Abcellera Biologics Inc stock is traded at $2.72, with a volume of 3.82M.
It is down -5.88% in the last 24 hours and up +8.80% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$2.89
Open:
$2.5
24h Volume:
3.82M
Relative Volume:
1.96
Market Cap:
$785.28M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-6.0444
EPS:
-0.45
Net Cash Flow:
$-121.38M
1W Performance:
-3.89%
1M Performance:
+8.80%
6M Performance:
-32.51%
1Y Performance:
-42.13%
1-Day Range:
$2.50
$2.79
1-Week Range:
$2.50
$2.90
52-Week Range:
$2.335
$6.055
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
2215 YUKON STREET, VANCOUVER
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Biologics (NASDAQ:ABCL) Receives "Hold" Rating from Benchmark - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Earns Buy Rating from Stifel Nicolaus - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Issues Earnings Results - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates - MSN
Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth - Investing.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Developments - GuruFocus.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Biologics Reports Q3 2024 Financial Results - TipRanks
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript - Nasdaq
AbCellera Reports Q3 2024 Business Results - BioSpace
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
Bright Horizons Family Solutions Inc (BFAM-N) QuotePress Release - The Globe and Mail
AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To K - GuruFocus.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
AbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on Monday - MarketBeat
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
AbCellera to Present at Upcoming Investor Conferences in November 2024 - Business Wire
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5%Here's What Happened - MarketBeat
AbCellera: A Platform To Pipeline Transition - Seeking Alpha
AbCellera Biologics (NASDAQ:ABCL) Trading Up 5.2%Here's What Happened - MarketBeat
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 - Lucknow Sentinel
Dark Forest Capital Management LP Buys 45,721 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Renaissance Technologies LLC - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Average Price Target from Analysts - MarketBeat
Wall Street SWOT: AbCellera stockBiotech firm's platform shows promise amid challenges - Investing.com
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - BioSpace
Citizens Financial Group Inc. RI Buys New Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Up 6.7% - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.5% - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume Increase - MarketBeat
Should You Follow Insider Buying on This Biotech Penny Stock? - Nasdaq
Should You Follow Insider Buying On This Biotech Penny Stock? - Barchart
AbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low at $2.39 - MarketBeat
Abcellera stock hits 52-week low at $2.4 amid market challenges - Investing.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Consensus Price Target from Analysts - MarketBeat
AbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025? - Insider Monkey
CEO, President & Chairperson of AbCellera Biologics Carl Hansen Buys More Stock - Simply Wall St
Carl Hansen Buys Handful Of Shares In AbCellera Biologics - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up to $2.53 - MarketBeat
AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024 - MSN
10 Best Multibagger Penny Stocks of 2025 - Insider Monkey
Thermopylae Holdings Ltd. buys $740k of AbCellera Biologics shares - Investing.com India
AbCellera to Present at Upcoming Investor Conferences in September - sharewise
Thermopylae Holdings Ltd. buys $740k of AbCellera Biologics shares By Investing.com - Investing.com UK
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):